KKKatsuya Komatsu

Katsuya Komatsu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katsuya Komatsu has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bilateral Anomalous Ophthalmic Artery Course With an Internal Carotid Artery Configuration Mimicking Moyamoya Angiopathy

    byĀ Ayumu Yamaoka, Katsuya Komatsu, Shogo Misumi, Yukinori Akiyama, Nobuhiro Mikuni

  • Open Access

    Stent-assisted coil embolization for a graft-related aneurysm following high-flow bypass: illustrative case

    byĀ Hiroki Ota, Ayumu Yamaoka, Issei Asari, Chie Kamada, Ryota Sato, Katsuya Komatsu, Sangnyon Kim, Yukinori Akiyama, Nobuhiro Mikuni

    BACKGROUND: High-flow bypass (HFB) combined with parent artery occlusion is an established treatment for complex cerebral aneurysms. Graft-related aneurysm (GA) at the anastomotic site is a rare late complication of HFB, and its optimal management remains poorly defined. The authors report a case of an unruptured GA that enlarged more than 10 years after HFB and was treated with stent-assisted coil embolization (SACE). OBSERVATIONS: A 50-year-old woman had undergone HFB using a radial artery (RA) graft for a cavernous segment aneurysm of the internal carotid artery 10 years earlier. A small aneurysmal dilation at the anastomosis was detected 2 years postoperatively, but long-term follow-up was interrupted. Ten years after the initial surgery, imaging revealed enlargement of a saccular GA with a bleb at the anastomotic site. SACE was performed through the tortuous RA graft using a distal access catheter for stable support, with deployment of an intracranial stent across the anastomosis to secure coil stability. Complete aneurysm occlusion was achieved without procedural complications. Follow-up cerebral angiography confirmed durable occlusion with preserved bypass patency. LESSONS: GA can occur as a late complication after HFB, underscoring the importance of long-term follow-up and medical management. Endovascular treatment may represent a less invasive treatment option in selected cases. https://thejns.org/doi/10.3171/CASE26249

  • Validity of Preoperative Screening Before Open-Heart Surgery in Reduction of Perioperative Ischemic Stroke

    byĀ Katsuya Komatsu, Takeshi Mikami, Yusuke Kimura, Yukinori Akiyama, Nobuyoshi Kawaharada, Nobuhiro Mikuni

  • Macrohistory of Moyamoya Disease Analyzed Using Artificial Intelligence

    byĀ Tomoyoshi Kuribara, Yukinori Akiyama, Takeshi Mikami, Katsuya Komatsu, Yusuke Kimura, Yasuhiro Takahashi, Kyoya Sakashita, Ryohei Chiba, Nobuhiro Mikuni

    Introduction: Moyamoya disease is characterized by progressive stenotic changes in the terminal segment of the internal carotid artery and the development of abnormal vascular networks called moyamoya vessels. The objective of this review was to provide a holistic view of the epidemiology, etiology, clinical findings, treatment, and pathogenesis of moyamoya disease. A literature search was performed in PubMed using the term ā€œmoyamoya disease,ā€ for articles published until 2021. Results: Artificial intelligence (AI) clustering was used to classify the articles into 5 clusters: (1) pathophysiology (23.5%); (2) clinical background (37.3%); (3) imaging (13.2%); (4) treatment (17.3%); and (5) genetics (8.7%). Many articles in the ā€œclinical backgroundā€ cluster were published from the 1970s. However, in the ā€œtreatmentā€ and ā€œgeneticsā€ clusters, the articles were published from the 2010s through 2021. In 2011, it was confirmed that a gene called Ringin protein 213 (RNF213) is a susceptibility gene for moyamoya disease. Since then, tremendous progress in genomic, transcriptomic, and epigenetic profiling (e.g., methylation profiling) has resulted in new concepts for classifying moyamoya disease. Our literature survey revealed that the pathogenesis involves aberrations of multiple signaling pathways through genetic mutations and altered gene expression. Conclusion: We analyzed the content vectors in abstracts using AI, and reviewed the pathophysiology, clinical background, radiological features, treatments, and genetic peculiarity of moyamoya disease.


  • Effects of polarity of bipolar sensorimotor direct cortical stimulation on intraoperative motor evoked potentials

    byĀ Shoto Yamada, Rei Enatsu, Yusuke Kimura, Katsuya Komatsu, Yukinori Akiyama, Takeshi Mikami, Satoko Ochi, Nobuhiro Mikuni


  • Additional Revascularization Using Multiple Burr Holes for PCA Involvement in Moyamoya Disease

    byĀ Chie Kamada, Tsukasa Hirano, Takeshi Mikami, Katsuya Komatsu, Hime Suzuki, Syuichi Tsushima, Yukinori Akiyama, Nobuhiro Mikuni


  • Preoperatively estimated graft flow rate contributes to the improvement of hemodynamics in revascularization for Moyamoya disease

    byĀ Tomoyoshi Kuribara, Takeshi Mikami, Katsuya Komatsu, Yusuke Kimura, Sangnyon Kim, Kei Miyata, Yukinori Akiyama, Rei Enatsu, Toru Hirano, Nobuhiro Mikuni


  • Open Access

    Changes in treatment strategy over time for arteriovenous malformation in a Japanese high-volume center

    byĀ Katsuya Komatsu, Yasushi Takagi, Akira Ishii, Takayuki Kikuchi, Yukihiro Yamao, Kazumichi Yoshida, Susumu Miyamoto

    Background: Despite rapid developments in devices used to treat arteriovenous malformation (AVM), a randomised trial of Unruptured Brain Arteriovenous malformations published in 2014 recommended conservative treatment for nonhemorrhagic AVM. The purpose of the current retrospective study was to confirm how AVM treatment in Japan has changed and to assess the safety of treatment for hemorrhagic and nonhemorrhagic AVMs. Methods: We enrolled 242 consecutive patients with AVM; each patient’s treatment was selected and performed at our hospital. The type of onset, Spetzler–Martin (S–M) grade, age, sex, selected treatment, mortality, and morbidity were compared between the first and second periods of our study. Results: In patients with grade I–III AVM, the selected treatment changed between the first and second periods; however, in grade IV and V patients, the selected treatment did not change. Overall, interventions by microsurgery alone decreased (p < 0.001), the proportion of total treatments including microsurgery decreased (p = 0.005), interventions using stereotactic radiosurgery (SRS) alone increased (p = 0.009), and interventions including SRS increased (p = 0.002). Morbidity associated with intervention was 0.92% in the first period and 0% in the second period, and mortality was 0.92% in the first period and 1.67% in the second. Conclusions: With the development of new devices, the selected treatment was changed in patients with S–M grade I–III AVM, but was not changed in patients with grade IV and V. The complication rate was low and did not change throughout the periods. These findings suggest that the safety of treatment depends on a full understanding of device development and the selection of proper treatment, not on hemorrhagic onset. Further treatment innovations are expected to change the treatment for grade IV and V AVMs.


  • Open Access

    Changes in treatment strategy over time for arteriovenous malformation in a Japanese high-volume center

    byĀ Katsuya Komatsu, Yasushi Takagi, Akira Ishii, Takayuki Kikuchi, Yukihiro Yamao, Kazumichi Yoshida, Susumu Miyamoto

    Background: Despite rapid developments in devices used to treat arteriovenous malformation (AVM), a randomised trial of Unruptured Brain Arteriovenous malformations published in 2014 recommended conservative treatment for nonhemorrhagic AVM. The purpose of the current retrospective study was to confirm how AVM treatment in Japan has changed and to assess the safety of treatment for hemorrhagic and nonhemorrhagic AVMs.Methods: We enrolled 242 consecutive patients with AVM; each patient’s treatment was selected and performed at our hospital. The type of onset, Spetzler–Martin (S–M) grade, age, sex, selected treatment, mortality, and morbidity were compared between the first and second periods of our study.Results: In patients with grade I–III AVM, the selected treatment changed between the first and second periods; however, in grade IV and V patients, the selected treatment did not change. Overall, interventions by microsurgery alone decreased (p < 0.001), the proportion of total treatments including microsurgery decreased (p = 0.005), interventions using stereotactic radiosurgery (SRS) alone increased (p = 0.009), and interventions including SRS increased (p = 0.002). Morbidity associated with intervention was 0.92% in the first period and 0% in the second period, and mortality was 0.92% in the first period and 1.67% in the second. Conclusions: With the development of new devices, the selected treatment was changed in patients with S–M grade I–III AVM, but was not changed in patients with grade IV and V. The complication rate was low and did not change throughout the periods. These findings suggest that the safety of treatment depends on a full understanding of device development and the selection of proper treatment, not on hemorrhagic onset. Further treatment innovations are expected to change the treatment for grade IV and V AVMs.

  • Recurrence Interval Within 1 Year Leads to Death in Patients with Grade 2 Meningioma

    byĀ Ryo Ukai, Masahiko Wanibuchi, Katsuya Komatsu, Yusuke Kimura, Yukinori Akiyama, Takeshi Mikami, Nobuhiro Mikuni